Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on the Severity and the Mortality of Acute Myocardial Infarction in Japan　— Analysis From the JROAD-DPC Database —

DOI Web Site 19 References
  • Kimura Mitsukuni
    Department of Cardiovascular Medicine, Kyushu University Faculty of Medicine
  • Matoba Tetsuya
    Department of Cardiovascular Medicine, Kyushu University Faculty of Medicine
  • Nakano Yasuhiro
    Department of Cardiovascular Medicine, Kyushu University Faculty of Medicine
  • Katsuki Shunsuke
    Department of Cardiovascular Medicine, Kyushu University Faculty of Medicine
  • Sakamoto Kazuo
    Department of Cardiovascular Medicine, Kyushu University Faculty of Medicine
  • Nishihara Masaaki
    Department of Cardiovascular Medicine, Kyushu University Faculty of Medicine
  • Nagata Takuya
    Department of Cardiovascular Medicine, Kyushu University Faculty of Medicine
  • Tahara Yoshio
    National Cerebral and Cardiovascular Center
  • Nagao Ken
    Cardiovascular Center, Nihon University Hospital
  • Okura Hiroyuki
    Department of Cardiology, Gifu University
  • Ikeda Takanori
    Department of Cardiovascular Medicine, Toho University
  • Nakai Michikazu
    Clinical Research Support Center, University of Miyazaki Hospital
  • Tsutsui Hiroyuki
    Department of Cardiovascular Medicine, Kyushu University Faculty of Medicine

Description

<p>Background: Coronavirus disease 2019 (COVID-19) has impacted on cardiovascular disease. However, it remains unclear whether the COVID-19 pandemic has impacted on disease severity and patients’ prognosis of acute myocardial infarction (AMI) in Japan.</p><p>Methods and Results: We retrospectively accumulated data from the Japanese Registry of All Cardiac and Vascular Diseases–Diagnosis Procedure Combination (JROAD-DPC) study (April 2019 to March 2021). Patients were divided into a before COVID-19 pandemic group or a during COVID-19 pandemic group. The proportion of patients who presented with cardiogenic shock (Killip class IV) was compared between groups, in association with 30-day mortality as the primary outcome. Killip class IV AMI significantly increased in the during COVID-19 pandemic group (15.7% vs. 14.5% in the before pandemic group, P<0.0001). The 30-day mortality was higher in the during COVID-19 pandemic group (9.6% vs. 9.2% in the before COVID-19 pandemic group, P=0.049). However, there was no significant difference in the adjusted 30-day mortality in each Killip class between the before and during COVID-19 pandemic groups.</p><p>Conclusions: During the early stage of the COVID-19 pandemic in Japan, 30-day mortality of AMI increased, mainly because of the increase of Killip class IV AMI patients. However, irrespective of the COVID-19 pandemic, the adjusted 30-day mortality of each Killip classification group was unchanged.</p>

Journal

  • Circulation Reports

    Circulation Reports 6 (6), 191-200, 2024-06-10

    The Japanese Circulation Society

References(19)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top